Helix BioMedix acquires stake in NuGlow
This article was originally published in The Rose Sheet
Executive Summary
Developer of bioactive peptides has acquired 30% ownership interest in NuGlow Cosmeceuticals, LLC, according to July 8 release. In addition, under a three-year supply agreement, Helix BioMedix will provide NuGlow with finished products including private-label cosmeceutical, sun-care and acne-care products. "Their advanced line of peptides and superior formulations will allow us to expand our offerings significantly," says NuGlow CEO Steven Sheiner. Helix President and CEO R. Stephen Beatty states: "NuGlow has established a tested, cost-effective and proven direct-response model that I believe will increase the value proposition for the commercialization of Helix BioMedix technologies." Helix expects that deal will enable it to reach a younger consumer than it currently captures with its Striking Skin Care line. Initial marketing campaign by NuGlow is anticipated to launch in the fall, targeting women 28 to 50 years of age
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.